By Fineline Cube 
Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) and Hangzhou Bio‑Sincerity (SHE: 301096) today signed a letter of intent to launch a joint drug‑development program that combines XtalPi’s AI‑driven discovery platform with Bio‑Sincerity’s advanced formulation capabilities.
Key Elements of the Agreement
- Research & Development Exchange – Bio‑Sincerity will commission XtalPi to conduct AI‑powered, robotics‑assisted lead identification across multiple therapeutic areas. In return, XtalPi will outsource formulation and early‑stage R&D work to Bio‑Sincerity’s high‑throughput facilities.
- Target Indications – The collaboration focuses on unmet clinical needs in pain, narcolepsy, oncology, autoimmune disease, and ophthalmology, aiming to accelerate pipeline incubation and clinical translation.
- Future Joint Venture – Both parties will evaluate forming a dedicated joint venture at a later stage to broaden commercial, regulatory, and manufacturing synergies.
Strategic Rationale
- Synergistic Technology Stack – XtalPi’s AI platform shortens hit‑to‑lead cycles, while Bio‑Sincerity’s formulation expertise reduces time‑to‑clinical‑ready candidates.
- Geographic Complementarity – The Shenzhen‑Hong Kong base of XtalPi offers deep regulatory connectivity in China, whereas Bio‑Sincerity’s Hangzhou operations provide high‑throughput manufacturing capacity.
- Portfolio Expansion – By co‑creating a diversified pipeline, the alliance seeks to capture significant market share in the rapidly growing global drug discovery landscape.
Next‑Step Roadmap
- Proof‑of‑Concept Studies on three lead candidates (one each in oncology, autoimmune disease, and ophthalmology).
- Regulatory Strategy Development with the China Food & Drug Administration (CFDA) for early‑stage approvals.
- Joint Venture Feasibility Analysis to assess capital structure, IP ownership, and revenue‑sharing models.-Fineline Info & Tech